Comparison of standard triple therapy, sequential therapy and moxifloxacin-based triple therapy for Helicobacter pylori infection: Patients' compliance and bacterial eradication rates

J Dig Dis. 2014 Sep;15(9):508-13. doi: 10.1111/1751-2980.12171.

Abstract

Objective: To compare the patients' compliance with and the efficacy of existing treatments for Helicobacter pylori eradication, including moxifloxacin-based triple therapy, sequential treatment and the standard treatment.

Methods: Patients with H. pylori infection were randomly assigned to three therapy groups. The triple therapy (MML) group was given moxifloxacin 400 mg/day, metronidazole 500 mg b.i.d. and lansoprazole 30 mg b.i.d. for 10 days. The sequential treatment (AL-CML) group was administrated amoxicillin 1 g b.i.d. and lansoprazole 30 mg b.i.d. for the first 5 days, followed by clarithromycin 500 mg b.i.d., metronidazole 500 mg b.i.d. and lansoprazole 30 mg b.i.d. for the second 5 days. The standard treatment (CAL) group received amoxicillin 1 g b.i.d., clarithromycin 500 mg b.i.d. and lansoprazole 30 mg b.i.d. for 14 days. The eradication rates were evaluated by per-protocol (PP) analysis and intention-to-treat (ITT) analysis.

Results: The eradication rates were 87.1, 85.9 and 85.2% by PP analysis and 87.1, 84.9 and 84.2% by ITT analysis in the MML, AL-CML and CAL group, respectively, and patients' compliance rates were 98.2, 96.5 and 97.1%, respectively. There were no significant differences in treatment efficacy and compliance rates in the MML, AL-CML and CAL groups (P > 0.05).

Conclusions: The present study revealed that standard triple therapy, sequential therapy and moxifloxacin-based triple therapy are all effective treatment regimens in terms of H. pylori eradication rates and compliance with therapy in Turkey.

Keywords: Helicobacter pylori; eradication rate; moxifloxacin; patients' compliance; resistance.

Publication types

  • Comparative Study
  • Randomized Controlled Trial

MeSH terms

  • Adult
  • Aged
  • Amoxicillin / therapeutic use
  • Anti-Bacterial Agents / therapeutic use*
  • Clarithromycin / therapeutic use
  • Drug Therapy, Combination
  • Female
  • Fluoroquinolones / therapeutic use*
  • Helicobacter Infections / drug therapy*
  • Helicobacter Infections / microbiology
  • Helicobacter pylori / isolation & purification*
  • Humans
  • Lansoprazole / therapeutic use
  • Male
  • Medication Adherence
  • Metronidazole / therapeutic use
  • Middle Aged
  • Moxifloxacin
  • Proton Pump Inhibitors / therapeutic use*
  • Treatment Outcome
  • Young Adult

Substances

  • Anti-Bacterial Agents
  • Fluoroquinolones
  • Proton Pump Inhibitors
  • Lansoprazole
  • Metronidazole
  • Amoxicillin
  • Clarithromycin
  • Moxifloxacin